Chemotherapy for Pancreatic Cancer

Recruiting in Palo Alto (17 mi)

Overseen ByErkut Borazanci, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: HonorHealth Research Institute

Stay on your current meds

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.

Eligibility Criteria

This trial is for adults with non-metastatic pancreatic cancer who haven't had chemotherapy or radiation. They must have a specific tumor marker elevated, normal organ function, and agree to use contraception if sexually active. Excluded are those with certain infections, recent major surgery, allergies to study drugs, lung conditions, heavy cannabinoid use, or other serious health risks.

Inclusion Criteria

My organs and bone marrow are functioning normally.

I am 18 years old or older.

My pancreatic cancer is confirmed and may or may not be removable by surgery.

I am able to care for myself but may not be able to do active work.

I have not had chemotherapy or radiation for pancreatic cancer.

My CA 19-9 levels are high, but my bilirubin is normal.

Exclusion Criteria

My cancer has spread to distant parts of my body.

I have a history of lung conditions like sarcoidosis or pulmonary fibrosis.

I do not have any ongoing serious infections requiring treatment.

I have been diagnosed with HIV, hepatitis B, or hepatitis C.

I have not had major surgery, except for a biopsy, in the last 4 weeks.

I do not have any serious heart rhythm problems.

Participant Groups

The trial tests a combination of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine in patients with pancreas cancer. It aims to see how this regimen affects the CA 19-9 tumor marker after up to six months before surgery.

1Treatment groups

Experimental Treatment

Group I: TreatmentExperimental Treatment4 Interventions

Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine

Cisplatin is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺 Approved in European Union as Platinol for: